Search

Your search keyword '"Fluconazole pharmacokinetics"' showing total 280 results

Search Constraints

Start Over You searched for: Descriptor "Fluconazole pharmacokinetics" Remove constraint Descriptor: "Fluconazole pharmacokinetics" Topic antifungal agents Remove constraint Topic: antifungal agents
280 results on '"Fluconazole pharmacokinetics"'

Search Results

1. Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections.

2. Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants.

Catalog

Books, media, physical & digital resources

3. Revolutionizing treatment for topical fungal infections: evaluating penetration-enhancer-containing vesicles as a fluconazole delivery system: Ex-vivo and in-vivo dermal testing.

4. Changes in fluconazole pharmacokinetics can impact on antifungal effectiveness in critically ill burn patients: a Pharmacokinetic-Pharmacodynamic (PK/PD) approach.

5. Development of antifungal fibrous ocular insert using freeze-drying technique.

6. Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.

7. Antifungal drug penetration in soft tissue abscesses: a comparative analysis.

8. Dual delivery systems combining nanocrystals and dissolving microneedles for improved local vaginal delivery of fluconazole.

9. Incorporation of Inclusion Complexes in the Dissolvable Microneedle Ocular Patch System for the Efficiency of Fluconazole in the Therapy of Fungal Keratitis.

10. Fabrication and Characterization of Pectin Films Containing Solid Lipid Nanoparticles for Buccal Delivery of Fluconazole.

11. Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants.

12. Fluconazole Population Pharmacokinetics after Fosfluconazole Administration and Dosing Optimization in Extremely Low-Birth-Weight Infants.

13. Lipo-PEG nano-ocular formulation successfully encapsulates hydrophilic fluconazole and traverses corneal and non-corneal path to reach posterior eye segment.

14. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.

15. Clinical pharmacokinetics and outcomes of oral fluconazole therapy in dogs and cats with naturally occurring fungal disease.

16. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.

17. From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.

18. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.

19. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.

20. The effect of fluconazole on oral methadone in dogs.

21. Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants.

22. Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis.

23. Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen.

24. Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization, and in vitro-in vivo evaluation.

25. [Therapeutic equivalence evaluated by in vitro studies of multisource pharmaceutical products: case studies of amoxicillin, doxycycline and fluconazole in Lima, Peru].

26. Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?

27. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

28. Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO.

29. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.

30. Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.

31. Gel in core carbosomes as novel ophthalmic vehicles with enhanced corneal permeation and residence.

32. Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin?

33. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.

34. Pulsed electric field-assisted sensitization of multidrug-resistant Candida albicans to antifungal drugs.

35. External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.

36. Bioactivity of Ceftazidime and Fluconazole Included in Polymethyl Methacrylate Bone Cement for Use in Arthroplasty.

37. Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.

38. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.

39. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.

40. New Generation of Fluconazole: A Review on Existing Researches and Technologies.

41. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.

42. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.

43. Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model.

44. Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.

45. Some pharmacokinetic indices of oral fluconazole administration to koalas (Phascolarctos cinereus) infected with cryptococcosis.

46. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.

47. Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis.

48. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.

49. Release of Fluconazole from Contact Lenses Using a Novel In Vitro Eye Model.

50. Uptake of azoles by lamb's lettuce (Valerianella locusta L.) grown in hydroponic conditions.